澳门老奇人论坛

Meeting Coverage >

ASN

Injectable PH1 Therapy Also Effective in Advanced CKD

Trial looked at patients with stages 3B through 5 chronic kidney disease

More Good News for Empagliflozin in Patients With Heart Failure

Slower renal function decline with SGLT-2 inhibitor in EMPEROR-Preserved trial

Investigational Oral CKD-Anemia Agent Effective, Safe

HIF-PHI daprodustat increased hemoglobin without hurting heart

Diuretic Bolstered Blood Pressure Control in Advanced CKD

But some safety signals did arise in 12-week trial

More Top Research From Kidney Week 2020

Additional studies on anemia, heart risk, and racial disparities in chronic kidney disease

Alternating Dual-Agent Tx Offers Better Remission in Nephropathy

Corticosteroid-cyclophosphamide bests sequential tacrolimus-rituximab in PMN

Finerenone Cuts Kidney, Heart Risks in CKD and T2D

Patients saw less hyperkalemia than with spironolactone but still some

Muscle Relaxant Tied to Severe Confusion in CKD Patients

Higher dose of baclofen associated with encephalopathy in older patients

New Agent Relieves Itching for Patients on Dialysis

"This is the first time anyone has shown anything that's worked"

SGLT-2 for Stage 3 CKD; Opioids for CKD; Kidney Transplant Discard & Disabilities

Roundup of more top abstracts from Kidney Week 2018

Time to Question Obesity-Based Cutoffs in Kidney Transplantation?

Study finds outcomes non-inferior to patients with BMI 35 and under

High-Dose Iron an Option for Maintenance Hemodialysis

High-dose noninferior to low-dose, required less erythropoiesis-stimulating agent

Sparsentan Cuts Proteinuria in Rare Kidney Disorder

Significant reduction in UP/C ratio with higher doses in focal segmental glomerulosclerosis patients

Acute Kidney Injury Linked with Higher Dementia Risk

Risk heightened even among those with full renal recovery

Kidney Docs Express Uncertainty About Women's Health

U.S., Canadian nephrologists especially lack confidence in contraceptive counseling

Home Hemodialysis Tied to Better Survival in Incident Patients

Kidney Outcomes Mixed Bag with Intensive Metabolic Care

Tight glucose control reduced, while intensive BP goals raised

Device May Ease Fistula Creation

Catheter-based, ultrasound-guided device had good long-term patency

Rituxan Has Promise in Idiopathic Nephropathy

B-cell targeting with rituximab seems as effective as with cyclosporine

CTA with IV Contrast May Mean Less Acute Kidney Injury

AKI seemed less likely than with intracoronary contrast administration

Boosting Water Intake Didn't Slow eGFR Decline in CKD

Water coaching did lead to better 24-hour urine volume

EHRs Help Identify Patients for CKD Care

Flagged at-risk patients in pragmatic trial with little added burden

ASN 2017: The Future of Personalized Nephrology

Tissue engineering, drug discovery challenges among highlight topics

Oral Treatment for T2D Tied to Renal Protection

SGLT2 inhibitor shows favorable effect on eGFR

Quick Steroid Withdrawal Works in Post-Transplant Diabetes

Incidence dropped from 39% to about 24%

Opioid Rx Linked to Higher Mortality in Dialysis Patients

Risks for hospitalization, dialysis discontinuation also higher

New Hospital Care Model Cut Readmissions, Boosted Satisfaction

Specialists urged to reconnect with generalist roots

Nephrologists at Kidney Week Blast Recertification Process

Consensus: stop making it a high-stakes exam

Stent Graft Keeps Vascular Access Clear

Should change practice, study leader says.

New Antibody Found in Membranous Nephropathy

Antibodies against THSD7A may be behind some cases.

Combo Angiotensin Tx Ups Kidney Risks

ATLANTA -- In yet another trial, dual blockade of the renin-angiotensin system (RAAS) didn't slow progression of kidney disease in diabetic patients and carried a higher risk of serious adverse events compared with monotherapy, researchers reported here.